Total trials
412
Active
109
Phase 3
51
Total enrollment
187,972
Pipeline matrix
Showing 40 of 45 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Belatacept | — | — | — | — | 2 | ||
| Rituximab | — | — | — | — | 5 | ||
| anticalcineurins | — | — | — | — | — | 1 | |
| Nefopam administration and prelevment | — | — | — | — | — | 1 | |
| Rituximab 1g IV | — | — | — | — | — | 1 | |
| Cyclophosphamide 50Mg Oral | — | — | — | — | — | 1 | |
| Gem/Nabpaclitaxel | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| Naropeine | — | — | — | — | — | 1 | |
| Baricitinib 4 MG | — | — | — | — | — | 1 | |
| ROVALCYTE | — | — | — | — | — | 1 | |
| Neoadjuvant chemotherapy | — | — | — | — | — | 1 | |
| Conversion to Belatacep | — | — | — | — | — | 1 | |
| Standard of care treatment (SOC regimen) with Tacrolimus | — | — | — | — | — | 1 | |
| Antibioprophylaxis | — | — | — | — | — | 1 | |
| 5 days Antibiotherapy | — | — | — | — | — | 1 | |
| Iloprost | — | — | — | — | — | 1 | |
| Domperidone 10mg | — | — | — | — | — | 1 | |
| intra-rectal botulinum toxin injections | — | — | — | — | — | 1 | |
| treatment adaptation guided by ctDNA variation | — | — | — | — | — | 1 | |
| standard management | — | — | — | — | — | 1 | |
| Sildenafil | — | — | — | — | — | 1 | |
| Adenuric | — | — | — | — | — | 1 | |
| Fosfomycun-trometamol | — | — | — | — | — | 1 | |
| aspirin intake | — | — | — | — | — | 1 | |
| Molecular analysis of exon 9 and 20 of PI3K | — | — | — | — | — | 1 | |
| blood intake | — | — | — | — | — | 1 | |
| Apremilast | — | — | — | — | — | 1 | |
| standard care + rotigotine at 4 mg/24h for 24 months. | — | — | — | — | — | 1 | |
| standard care for 24 months. | — | — | — | — | — | 1 | |
| SVF injection into wrist | — | — | — | — | — | 1 | |
| Bosentan | — | — | — | — | — | 1 | |
| treatment with DIELEN® Protect | — | — | — | — | — | 1 | |
| treatment with placebo of DIELEN® Protect | — | — | — | — | — | 1 | |
| Aprepitant 125 and 80Mg Oral | — | — | — | — | — | 1 | |
| Fentanyl - Inhalation by facial nebulization | — | — | — | — | — | 1 | |
| Fentanyl - Nebulisation | — | — | — | — | — | 1 | |
| blood sample | — | — | — | — | 3 | ||
| Blood test | — | — | — | — | — | 2 | |
| Dosage concentration of piperacillin and tazobactam | — | — | — | — | — | 1 |
5 more active programs hidden
Next readouts
- 2026-04
- 2026-05-13
- 2026-08
- 2026-10-02
- 2026-12
- 2026-12
- 2027-01-01
- 2027-01-15
- 2027-02
- 2027-02
Top conditions
- Irritable Bowel Syndrome11
- Anesthesia8
- Fecal Incontinence7
- Aortic Valve Stenosis6
- Obesity6
- Rheumatoid Arthritis6
- Surgery5
- Septic Shock5
Frequently asked questions about University Hospital, Rouen
- How many clinical trials does University Hospital, Rouen have on ClinicalTrials.gov?
- University Hospital, Rouen is listed as the lead sponsor on 412 clinical trials in ClinicalTrials.gov, 109 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Rouen's trials are in Phase 3?
- 51 of University Hospital, Rouen's trials are in Phase 3, spread across 45 active drug programs.
- What therapeutic areas does University Hospital, Rouen focus on?
- University Hospital, Rouen's most-studied conditions on ClinicalTrials.gov are Irritable Bowel Syndrome, Anesthesia, Fecal Incontinence, Aortic Valve Stenosis, Obesity.
- When are University Hospital, Rouen's next clinical trial readouts?
- University Hospital, Rouen has 10 upcoming primary-completion readouts tracked here; the soonest is “Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies”, expected around 2026-04.